<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Essential</title>
	<atom:link href="http://www.tapanray.in/tag/essential/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>An Interesting demand: No Price Control For OTC Drugs</title>
		<link>http://www.tapanray.in/an-interesting-demand-no-price-control-for-otc-drugs/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=an-interesting-demand-no-price-control-for-otc-drugs</link>
		<comments>http://www.tapanray.in/an-interesting-demand-no-price-control-for-otc-drugs/#comments</comments>
		<pubDate>Mon, 19 Nov 2018 00:00:50 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[Association]]></category>
		<category><![CDATA[benefits]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[decontrol]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Essential]]></category>
		<category><![CDATA[Expenses]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[oop]]></category>
		<category><![CDATA[OTC]]></category>
		<category><![CDATA[out of pocket]]></category>
		<category><![CDATA[outside]]></category>
		<category><![CDATA[Over The Counter]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Promotion]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[switch]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Trade]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9286</guid>
		<description><![CDATA[Since over a decade, some pharma trade organizations operating in India, have been advocating for a separate regulatory policy for ‘Over The Counter (OTC)’ drugs, which can be legally sold without any medical prescriptions. Such a new policy initiative, if taken by &#8230; <a href="http://www.tapanray.in/an-interesting-demand-no-price-control-for-otc-drugs/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/an-interesting-demand-no-price-control-for-otc-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Union Budget 2018: The &#8216;WOW&#8217; Moment for Indian Healthcare?</title>
		<link>http://www.tapanray.in/union-budget-2018-the-wow-moment-for-indian-healthcare/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=union-budget-2018-the-wow-moment-for-indian-healthcare</link>
		<comments>http://www.tapanray.in/union-budget-2018-the-wow-moment-for-indian-healthcare/#comments</comments>
		<pubDate>Mon, 05 Feb 2018 00:00:00 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2017]]></category>
		<category><![CDATA[2018]]></category>
		<category><![CDATA[2019]]></category>
		<category><![CDATA[ABP]]></category>
		<category><![CDATA[Ayushman Bharat Program]]></category>
		<category><![CDATA[Budget]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[centers]]></category>
		<category><![CDATA[driven]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Essential]]></category>
		<category><![CDATA[HCP]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[HPS]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[insurance]]></category>
		<category><![CDATA[moment]]></category>
		<category><![CDATA[NHP]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[scheme]]></category>
		<category><![CDATA[State]]></category>
		<category><![CDATA[Subject]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Union]]></category>
		<category><![CDATA[wellness]]></category>
		<category><![CDATA[WOW]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8825</guid>
		<description><![CDATA[The 2018-19 Union Budget proposals, presented before the Parliament on February 01, 2018. Especially for those who take keen interest in the Indian healthcare environment, was there a ‘WOW’ moment in the budget? Some say, this long-awaited moment came with &#8230; <a href="http://www.tapanray.in/union-budget-2018-the-wow-moment-for-indian-healthcare/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/union-budget-2018-the-wow-moment-for-indian-healthcare/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Next Frontier: Frugal Innovation For High-Tech Drugs</title>
		<link>http://www.tapanray.in/the-next-frontier-frugal-innovation-for-high-tech-drugs/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-next-frontier-frugal-innovation-for-high-tech-drugs</link>
		<comments>http://www.tapanray.in/the-next-frontier-frugal-innovation-for-high-tech-drugs/#comments</comments>
		<pubDate>Mon, 30 May 2016 00:00:42 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[ABBvie]]></category>
		<category><![CDATA[arbitrary]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Essential]]></category>
		<category><![CDATA[facade]]></category>
		<category><![CDATA[Frugal]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[life]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Models]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[saving]]></category>
		<category><![CDATA[Stemcentrx]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[tech]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7655</guid>
		<description><![CDATA[Should drug innovation models remain as expensive as what these are claimed to be now by the global pharma industry, in general? Finding a credible, appropriately quantifiable, and generally acceptable answer to this question is critical. It won’t, then, just &#8230; <a href="http://www.tapanray.in/the-next-frontier-frugal-innovation-for-high-tech-drugs/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-next-frontier-frugal-innovation-for-high-tech-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Arbitrary Pricing of Essential Drugs Invites State Intervention</title>
		<link>http://www.tapanray.in/arbitrary-pricing-of-essential-drugs-invites-state-intervention/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=arbitrary-pricing-of-essential-drugs-invites-state-intervention</link>
		<comments>http://www.tapanray.in/arbitrary-pricing-of-essential-drugs-invites-state-intervention/#comments</comments>
		<pubDate>Mon, 23 May 2016 00:00:33 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[2015]]></category>
		<category><![CDATA[arbitrary]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[Combiflam]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[economy]]></category>
		<category><![CDATA[Essential]]></category>
		<category><![CDATA[Free]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Payment]]></category>
		<category><![CDATA[PhRMA]]></category>
		<category><![CDATA[premium]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[winner]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7644</guid>
		<description><![CDATA[Arbitrary drug pricing has now become a subject of a raging debate, all over the globe. It involves both patented and generic drugs, as we have recently witnessed in the largest pharma market in the world – the United States. &#8230; <a href="http://www.tapanray.in/arbitrary-pricing-of-essential-drugs-invites-state-intervention/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/arbitrary-pricing-of-essential-drugs-invites-state-intervention/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Is Drug Price Control The Key Growth Barrier For Indian Pharma Industry?</title>
		<link>http://www.tapanray.in/is-drug-price-control-the-key-growth-barrier-for-indian-pharma-industry/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=is-drug-price-control-the-key-growth-barrier-for-indian-pharma-industry</link>
		<comments>http://www.tapanray.in/is-drug-price-control-the-key-growth-barrier-for-indian-pharma-industry/#comments</comments>
		<pubDate>Mon, 19 Oct 2015 00:00:14 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[1995]]></category>
		<category><![CDATA[2011]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[AIOCD]]></category>
		<category><![CDATA[AIOCD-AWACS]]></category>
		<category><![CDATA[apex]]></category>
		<category><![CDATA[Atorvastatin]]></category>
		<category><![CDATA[AWACS]]></category>
		<category><![CDATA[barrier]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[consumer]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[core]]></category>
		<category><![CDATA[corollary]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[Crocin Advance]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[driver]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Essential]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[health care UHC]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[hikes]]></category>
		<category><![CDATA[IMS]]></category>
		<category><![CDATA[increases]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[IPM]]></category>
		<category><![CDATA[key]]></category>
		<category><![CDATA[Maharashtra]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[Para 19]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[safeguard]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Universal]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7183</guid>
		<description><![CDATA[The corollary of the above headline could well be: “Are drug price hikes the key growth driver for the Indian Pharmaceutical Market (IPM)?” Whenever the first question, as appears in the headline of this article: “Is drug price control a &#8230; <a href="http://www.tapanray.in/is-drug-price-control-the-key-growth-barrier-for-indian-pharma-industry/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/is-drug-price-control-the-key-growth-barrier-for-indian-pharma-industry/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>India To Expand NLEM 2011: A Step In The Right Direction</title>
		<link>http://www.tapanray.in/india-to-expand-nlem-2011-a-step-in-the-right-direction/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=india-to-expand-nlem-2011-a-step-in-the-right-direction</link>
		<comments>http://www.tapanray.in/india-to-expand-nlem-2011-a-step-in-the-right-direction/#comments</comments>
		<pubDate>Mon, 11 May 2015 00:00:53 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[1995]]></category>
		<category><![CDATA[2002]]></category>
		<category><![CDATA[2011]]></category>
		<category><![CDATA[2012]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[2014-15]]></category>
		<category><![CDATA[2015-16]]></category>
		<category><![CDATA[Ananth Kumar]]></category>
		<category><![CDATA[BMJ]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[direction]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Essential]]></category>
		<category><![CDATA[expand]]></category>
		<category><![CDATA[Expansion]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[ICMR]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Katoch]]></category>
		<category><![CDATA[List]]></category>
		<category><![CDATA[Lok Sabha]]></category>
		<category><![CDATA[Margaret Chan]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[NPPP]]></category>
		<category><![CDATA[Parliament]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[PHFI]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[public health foundation]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reuters]]></category>
		<category><![CDATA[right]]></category>
		<category><![CDATA[step]]></category>
		<category><![CDATA[STG]]></category>
		<category><![CDATA[Supreme Court]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[union budget]]></category>
		<category><![CDATA[W.H.O]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6591</guid>
		<description><![CDATA[Responding to growing discontentment on the flawed National List of Essential Medicines 2011 (NLEM 2011) and equally vociferous demand for its urgent rectification, on May 5, 2015, in a written reply to the Lower House of Indian Parliament (Lok Sabha) &#8230; <a href="http://www.tapanray.in/india-to-expand-nlem-2011-a-step-in-the-right-direction/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/india-to-expand-nlem-2011-a-step-in-the-right-direction/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Cheaper Drugs: Happy Patients: Angry Industry</title>
		<link>http://www.tapanray.in/cheaper-drugs-happy-patients-angry-industry/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=cheaper-drugs-happy-patients-angry-industry</link>
		<comments>http://www.tapanray.in/cheaper-drugs-happy-patients-angry-industry/#comments</comments>
		<pubDate>Mon, 21 Jul 2014 00:00:15 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA['fire in the blood']]></category>
		<category><![CDATA[19]]></category>
		<category><![CDATA[1995]]></category>
		<category><![CDATA[2011]]></category>
		<category><![CDATA[2012]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[Ananth]]></category>
		<category><![CDATA[angry]]></category>
		<category><![CDATA[Based]]></category>
		<category><![CDATA[cardiac]]></category>
		<category><![CDATA[cardiovascular]]></category>
		<category><![CDATA[Cheaper]]></category>
		<category><![CDATA[chemicals]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[diabetes]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Essential]]></category>
		<category><![CDATA[Fertilizers]]></category>
		<category><![CDATA[Happy]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[Kumar]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[NPPP]]></category>
		<category><![CDATA[para]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5640</guid>
		<description><![CDATA[Recent price reductions of a number of cardiovascular and diabetes drugs falling outside the National List of Essential Medicines 2011 (NLEM 2011), have attracted fury of the pharma industry . By a notification dated July 10, 2014, the National Pharmaceutical &#8230; <a href="http://www.tapanray.in/cheaper-drugs-happy-patients-angry-industry/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/cheaper-drugs-happy-patients-angry-industry/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Public Healthcare Space: Evaluating Three Fresh Edicts</title>
		<link>http://www.tapanray.in/public-healthcare-space-evaluating-three-fresh-edicts/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=public-healthcare-space-evaluating-three-fresh-edicts</link>
		<comments>http://www.tapanray.in/public-healthcare-space-evaluating-three-fresh-edicts/#comments</comments>
		<pubDate>Mon, 02 Dec 2013 00:00:12 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2010]]></category>
		<category><![CDATA[CE]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[CMSS]]></category>
		<category><![CDATA[Council]]></category>
		<category><![CDATA[edicts]]></category>
		<category><![CDATA[Essential]]></category>
		<category><![CDATA[Establishment Act]]></category>
		<category><![CDATA[Establishments]]></category>
		<category><![CDATA[evaluating]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[Free]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[laudative]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[NCCE]]></category>
		<category><![CDATA[off]]></category>
		<category><![CDATA[oop]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[ready]]></category>
		<category><![CDATA[Standard]]></category>
		<category><![CDATA[steps]]></category>
		<category><![CDATA[STG]]></category>
		<category><![CDATA[systems]]></category>
		<category><![CDATA[take]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[welcoming]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4307</guid>
		<description><![CDATA[Medicines constitute a significant cost component of modern healthcare systems across the world. However, in India the situation is even worse, where as per recent studies, drugs contribute as high as around 70 percent of the total treatment cost. This &#8230; <a href="http://www.tapanray.in/public-healthcare-space-evaluating-three-fresh-edicts/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/public-healthcare-space-evaluating-three-fresh-edicts/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>FDC Saga: Defiant Manufacturers, Sloppy Regulators and Humongous Inaction</title>
		<link>http://www.tapanray.in/fdc-saga-defiant-manufacturers-sloppy-regulators-and-humongous-inaction/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=fdc-saga-defiant-manufacturers-sloppy-regulators-and-humongous-inaction</link>
		<comments>http://www.tapanray.in/fdc-saga-defiant-manufacturers-sloppy-regulators-and-humongous-inaction/#comments</comments>
		<pubDate>Mon, 15 Jul 2013 00:00:59 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[attractiveness]]></category>
		<category><![CDATA[bioequivalence]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Combination]]></category>
		<category><![CDATA[controller]]></category>
		<category><![CDATA[cosmetics]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[D&C]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[DGHS]]></category>
		<category><![CDATA[Dose]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[DTAB]]></category>
		<category><![CDATA[dubious]]></category>
		<category><![CDATA[efficacy]]></category>
		<category><![CDATA[Essential]]></category>
		<category><![CDATA[FDC]]></category>
		<category><![CDATA[Fixed]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[handsome]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[humongous]]></category>
		<category><![CDATA[inaction]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[madras]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Ministry]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[notification]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pioglitazone]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulation]]></category>
		<category><![CDATA[regulator]]></category>
		<category><![CDATA[retraction]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Saga]]></category>
		<category><![CDATA[scenario]]></category>
		<category><![CDATA[slack]]></category>
		<category><![CDATA[sloppy]]></category>
		<category><![CDATA[State]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2921</guid>
		<description><![CDATA[&#8220;TO SIN BY SILENCE WHEN THEY SHOULD PROTEST MAKES COWARDS OF MEN&#8221;       &#8211; Abraham Lincoln The ghost of untested, irrational and even of bizarre kind of Fixed Dose Combination (FDC) drugs, which continue to be launched, promoted, prescribed &#8230; <a href="http://www.tapanray.in/fdc-saga-defiant-manufacturers-sloppy-regulators-and-humongous-inaction/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/fdc-saga-defiant-manufacturers-sloppy-regulators-and-humongous-inaction/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>New Drug Price Control Order of India: Is it Directionally Right Improving Access to Medicines?</title>
		<link>http://www.tapanray.in/new-drug-price-control-order-of-india-is-it-directionally-right-improving-access-to-medicines/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=new-drug-price-control-order-of-india-is-it-directionally-right-improving-access-to-medicines</link>
		<comments>http://www.tapanray.in/new-drug-price-control-order-of-india-is-it-directionally-right-improving-access-to-medicines/#comments</comments>
		<pubDate>Mon, 27 May 2013 00:00:19 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2002]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[accuracy]]></category>
		<category><![CDATA[AIOCD]]></category>
		<category><![CDATA[AWACS]]></category>
		<category><![CDATA[Based]]></category>
		<category><![CDATA[benefit]]></category>
		<category><![CDATA[ceiling]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[Challenging]]></category>
		<category><![CDATA[CO]]></category>
		<category><![CDATA[consumers]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[DPCO2013]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Essential]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[implementation]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Karnataka]]></category>
		<category><![CDATA[litigation]]></category>
		<category><![CDATA[margin]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[methodology]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[NLEM 2011]]></category>
		<category><![CDATA[notification]]></category>
		<category><![CDATA[Order]]></category>
		<category><![CDATA[outsourced]]></category>
		<category><![CDATA[overview]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PIL]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[retail]]></category>
		<category><![CDATA[Ringside]]></category>
		<category><![CDATA[span]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[view]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2546</guid>
		<description><![CDATA[The last Drug Policy of India was announced in 2002, which was subsequently challenged by a Public Interest Litigation (PIL) in the Karnataka High Court on the ground of being inflationary in nature. The Honorable Court by its order dated &#8230; <a href="http://www.tapanray.in/new-drug-price-control-order-of-india-is-it-directionally-right-improving-access-to-medicines/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/new-drug-price-control-order-of-india-is-it-directionally-right-improving-access-to-medicines/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
